2024 Nasdaq rxrx - Check out our RXRX stock analysis, current RXRX quote, charts, and historical prices for Recursion Pharmaceuticals Inc Cl A stock. ... (NASDAQ:RXRX) From Seeking Alpha Oct 19, 2023 Royalty Pharma ...

 
Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in.... Nasdaq rxrx

That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention. Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock. Since then ...Recursion is forging key relationships with powerful collaborators. The young biotech's valuation is also looking a lot better now. However, its finances are nowhere near breakeven yet. NASDAQ: RXRX. Recursion Pharmaceuticals. Market Cap. $1B. Today's Change. (13.00%) $0.68.Plus Therapeutics, Inc. (NASDAQ:PSTV) will present at the Conference on Brain Metastases, hosted by the Society for Neuro-Oncology, data from one planned clinical trial and one completed ...Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded.Nov 29, 2023 · 4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price. Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart. Buy RXRX stock at Webull.As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.Based on analysts offering 12 month price targets for RXRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .RXRX POWR Grades. RXRX scores best on the Growth dimension, with a Growth rank ahead of 20.42% of US stocks. ... (NASDAQ:RXRX), sold 18,000 shares of the company on November 15, 2023. Yahoo | November 18, 2023. Insider Sell: CFO Michael Secora Offloads 50,000 Shares of Recursion Pharmaceuticals Inc (RXRX)5 Eki 2023 ... The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share.After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.45%) on July 12, Recursion Pharmaceuticals ( RXRX 10.49%) saw its stock blast off, rising 87% over the following ...RXRX: Recursion Pharmaceuticals Inc Stock Price Quote - NASDAQ GS - Bloomberg Subscribe S&P 500 4,556.62 +0.41% Nasdaq 14,265.86 +0.46% Crude Oil …Oct 11, 2022 · Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ... At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug candidates. Since then, RXRX dropped to about $6 a ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Netflix Inc (NASDAQ:NFLX): Bought 2,490 shares of the movie streaming company, representing about 0.199% of the ETF. Netflix stock closed 1.45% higher at $554.44 on Monday. It has a 52-week high ...Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...Export data to Excel for your own analysis. Start Your 30-Day Free Trial. RXRX's current price target is $11.20. Learn why top analysts are making this stock …Find the latest dividend history for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.(NASDAQ:RXRX), which I spoke about on Aug. 8. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug ...Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah. Headquarters Location. 41 South Rio Grande Street . Salt Lake City, Utah, 84101,Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at …$6.92 0.14 [2.06%] Last update: 10:53AM (Delayed 15-Minutes) Get Real Time Here $6.85 -0.0700 [-1.01%] Profile News Analyst Ratings Guidance Dividends …Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ...Yet, risky stocks can also often offer attractive upside potential. Let's look at two examples: Recursion Pharmaceuticals ( RXRX 4.40%) and Madrigal Pharmaceuticals ( MDGL 1.83%). These two ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Nov 30, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better stock?We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking. SALT LAKE CITY, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2022.Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Shares of Recursion Pharmaceuticals (RXRX 4.89%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.Nov 24, 2023 · The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors? Jul 6, 2023 · Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares. Recursion Pharmaceuticals (NASDAQ: RXRX) exploded in July on the strength of hot news—a $50 million direct investment from Nvidia (NASDAQ: NVDA). Since that month’s high, shares are back in ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ...A lot of healthcare companies are seeking to brandish their AI bonafides, but Recursion Pharmaceuticals (RXRX 7.88%), and GE Healthcare Technologies (GEHC 1.39%) are already using AI to boost ...The US$14.13 analyst price target for RXRX is 3.5% less than our estimate of fair value Does the July share price for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) reflect what it's really worth?2,015.20 +2.80(+0.14%) Advertisement Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 6.53 -0.33 (-4.81%) …Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio biotechnology company. It is focused on utilizing advanced technologies in biology, chemistry, automation, and computer science to discover and design therapeutics. Latest Recursion Pharmaceuticals Inc (RXRX:NSQ) share price with interactive charts, historical prices, comparative ...12 Tem 2023 ... buy RXRX Stock? or time to buy Nvidia Stock Price? A portion of this ... The Stock Market Will Finally Move (TOMORROW!) StockedUp New 6.4K ...Benzinga. Apr. 25, 2021, 10:33 PM. Cathie Wood-led Ark Investment Management on Friday snapped up another 221,167 shares of the cryptocurrency exchange Coinbase Global Inc (NASDAQ:COIN) worth ...Microsoft Corporation Common Stock. $376.39 +0.22 +0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ... Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements.4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...Recursion Pharmaceuticals Inc (NASDAQ:RXRX). 7.38. Delayed Data. As of Dec 01. +0.53 / +7.74%. Today's Change. 4.54. Today|||52-Week Range. 16.75. -4.28%. Year- ...Today, we take our first look at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead?Jul 12, 2023 · RXRX.O. Official Data Partner. Latest Trade. trading higher 7.14 USD. Change 0.12 % Change + 1.71% Positive ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment July 12, 2023. RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After Hours Volume:...Coinbase Global Inc (NASDAQ:COIN) Zymergen Inc (NASDAQ:ZY) Signify Health Inc (NYSE:SGFY) Repare Therapeutics Inc (NASDAQ:RPTX) Recursion Pharmaceuticals Inc (NASDAQ:RXRX) 908 Devices Inc (NASDAQ ...2023-09-11 09:35:31 ET. Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug development, it could soon mark itself as the leading competitor in a space that will probably prove to be quite lucrative.Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksRXRX Recursion Pharmaceuticals Inc Bayer and Recursion Focus Research Collaboration on Oncology. Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) ...MarketWatch IBD Sign In Recursion Pharmaceuticals Inc. RXRX (U.S.: Nasdaq) Overview News Recursion Pharmaceuticals Inc. No significant news for in the …That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...Or, we can look back at Recursion Pharmaceuticals. (NASDAQ:RXRX), which I spoke about on Aug. 8.At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create ...Industry. Biotechnology. No executives to display. Corporate headquarters. --, --. Find real-time RXRX - Recursion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN ... Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.In a notable insider transaction, Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on November 15, 2023.If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Nov 29, 2023 · 4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price. 4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price.The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on November 13, 2023. The analyst firm set a price target for $10.00 expecting RXRX to rise to ...Recursion Pharmaceuticals (NASDAQ:RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ:NVDA) in July rocketed its shares.For a biotech like Recursion Pharmaceuticals (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...5 Eki 2023 ... The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share.Recursion Pharmaceuticals (NASDAQ:RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Recursion is forging key relationships with powerful collaborators. The young biotech's valuation is also looking a lot better now. However, its finances are nowhere near breakeven yet. NASDAQ: RXRX. Recursion Pharmaceuticals. Market Cap. $1B. Today's Change. (13.00%) $0.68.Nov 26, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (0.43%) $0.03. Current Price. $7.05. ... (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as ... As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you …Jul 12, 2023 · RXRX.O. Official Data Partner. Latest Trade. trading higher 7.14 USD. Change 0.12 % Change + 1.71% Positive ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment July 12, 2023. Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah.About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a ...SALT LAKE CITY, May 12, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...9 Kas 2023 ... ... (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. The two companies are working ...Nasdaq rxrx

Find the latest dividend history for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.. Nasdaq rxrx

nasdaq rxrx

Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Pre-Market Stock Quotes ...Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) last month posted second-quarter results. GAAP EPS in the quarter came in at -$0.38. Revenue in the period jumped 42.9% year over year to $11 million.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the top stock picks of Samsara BioCapital along with IVERIC bio, Inc. (NASDAQ:ISEE), Sutro Biopharma, Inc. (NASDAQ:STRO) and Forma ...Nov 26, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (0.43%) $0.03. Current Price. $7.05. ... (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as ... RXRX Recursion Pharmaceuticals Inc Current Report Filing (8-k) The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed “filed” for purposes of Section 18 of ...Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksSALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported ...Nov 30, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better stock?We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking. Cathie Wood can't get enough of Recursion Pharmaceuticals (NASDAQ: RXRX) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...Nov 9, 2023 · About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a ... Recursion Pharmaceuticals Inc (NASDAQ:RXRX) initiated Phase 2/3 POPLAR-NF2 trial of REC-2282 for progressive neurofibromatosis type 2-mutated meningiomas, tumors that form on the membrane that ...Find the latest Institutional Holdings data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become ...It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...Chris Gibson. Co-Founder/CEO Recursion: a biotech scaling more like a tech company - Nasdaq:RXRX | Reimagining the Future of Biotech. 6y. As we continue building Recursion Pharmaceuticals, we ...12 Tem 2023 ... SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business ...Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its third quarter ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After Hours Volume:... Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a ...Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX 7.88%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock. Since then ...Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals ( RXRX -2.84%). Earlier this year, the company's shares skyrocketed after it announced a partnership with the ...Coinbase Global Inc (NASDAQ:COIN) Zymergen Inc (NASDAQ:ZY) Signify Health Inc (NYSE:SGFY) Repare Therapeutics Inc (NASDAQ:RPTX) Recursion Pharmaceuticals Inc (NASDAQ:RXRX) 908 Devices Inc (NASDAQ ...If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both ...Today, we take our first look at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead?Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ... NASDAQ. Market Closed. RECURSION PHARMACEUTICALS INC (RXRX). 6.86 0.08 (1.18%) +0.08 (+1.18%) 0.08 (1.18%). As of 24 November 2023 02:00 PM EST. Currency USD.Find the latest dividend history for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...SALT LAKE CITY, July 12, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry ...Chief Business Officer (Nasdaq: RXRX). Recursion University of Cambridge. St Petersburg, Florida, United States. 3K followers 500+ connections. See your mutual ...Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development ...Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements.Recursion Pharmaceuticals Inc (NASDAQ:RXRX) 7.06 Delayed Data As of Nov 17 +0.39 / +5.85% Today’s Change 4.54 Today ||| 52-Week Range 16.75 -8.43% Year-to-Date …Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Nov 30, 2023 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed...Nov 27, 2023 · Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This will be used […] Overview News Recursion Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data N/A EPS (TTM) $-1.47 $1.48 B ) Shares Sold Short 35.50 M Change from Last 7.40% Percent...In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings.Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.View the latest Nasdaq Inc. (NDAQ) stock price, news, historical charts, analyst ratings and financial information from WSJ.SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...Nov 30, 2023 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. 13 Tem 2023 ... The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation;” and so on. But rather more ...According to the issued ratings of 4 analysts in the last year, the consensus rating for Recursion Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy rating for RXRX. The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of …Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Today, we take our first look at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead?Nov 16, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ... Xerox Holdings Corporation Common Stock (XRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.RXRX Recursion Pharmaceuticals Inc Bayer and Recursion Focus Research Collaboration on Oncology. Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) .... Steam powered cars